Merck & Co. and its partner Ridgeback Biotherapeutics sign an agreement with UNICEF to distribute up to 3 million courses of their COVID-19 antiviral pill molnupiravir to 100 low and middle-income countries in the first half of the year.
Merck & Co. and its partner Ridgeback Biotherapeutics signs an agreement with UNICEF to distribute up to 3 million courses of their COVID-19 antiviral pill molnupiravir to 100 low and middle-income countries in the first half of 2022.
Merck & Co. and its partner Ridgeback Biotherapeutics sign an agreement with UNICEF to distribute up to 3 million courses of their COVID-19 antiviral pill molnupiravir to 100 low and middle-income countries in the first half of theyear.